WARRINGTON, Pa., Nov. 8, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that Craig Frasier, President and Chief Executive Officer, will present at the Stifel 2016 Healthcare Conference at the Lotte New York Palace Hotel in New York. The presentation is scheduled for Tuesday, November 15, 2016 at 8:45 am ET.
A live audio webcast will be available via the events page of the Windtree website at http://windtreetx.investorroom.com/events. A replay of the presentation will be archived on the Windtree website for 30 days for those unable to listen live.
About Windtree Therapeutics
Windtree Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. Windtree's proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree is focused initially on improving the management of respiratory distress syndrome (RDS) in premature infants and believes that its proprietary technology may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies.
For more information, please visit the Company's website at www.windtreetx.com.
SOURCE Windtree Therapeutics, Inc.